

## Pubblicazioni dal 1993 al 2014

- 1) Impact of Cytomegalovirus Replication and CMV serostatus on the Outcome of Patients with B-cell Lymphoma after Allogeneic Stem Cell Transplantation. Mariotti J, Maura F, Spina F, Roncari L, Dodero A, Farina L, Montefusco V, **Carniti C**, Sarina B, Patriarca F, Rambaldi A, Onida F, Olivieri A, Zallio F, Corradini P. *Biol Blood Marrow Transplant*. 2014 Feb 27.]
- 2) Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. Corradini P, **Carniti C**. *Methods Mol Biol*. 2014;1109:209-37
- 3) Adipose tissue displays trophic properties on normal lung cellular components without promoting cancer cells growth. Andriani F, Facchinetti F, Furia S, Roz L, Bursomanno S, Bertolini G, **Carniti C**, Sozzi G, Pastorino U. *J Cell Physiol*. 2013;228:1166-73
- 4) Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. Mariotti J, Spina F, **Carniti C**, Anselmi G, Lucini D, Vendramin A, Pregliasco F, Corradini P. *Eur J Haematol*. 2012;89:111-9.
- 5) Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways. Caccia D, Zanetti Domingues L, Miccichè F, De Bortoli M, **Carniti C**, Mondellini P, Bongarzone I. *J Proteome Res*. 2011;10:4196-207
- 6) Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. Fracchiolla NS, Todoerti K, Bertazzi PA, Servida F, Corradini P, **Carniti C**, Colombi A, Cecilia Pesatori A, Neri A, Deliliers GL. *Toxicology*. 2011;283:18-23.
- 7) Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. Ruella M, Rocci A, Ricca I, **Carniti C**, Bodoni CL, Ladetto M, Caracciolo D, Boccadoro M, Carlo-Stella C, Corradini P, Tarella C. *Bone Marrow Transplant*. 2010;45:505-12.
- 8) Radioimmunotherapy and secondary leukemia: a case report. Magni M, Di Nicola M, Testi A, Cabras A, Devizzi L, Guidetti A, Matteucci P, Viviani S, Bonfante V, **Carniti C**, Ricca I, Carbone A, Carlo-Stella C, Gianni AM. *Leuk Res*. 2010;34:e1-4.
- 9) Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Farina L, **Carniti C**, Dodero A, Vendramin A, Raganato A, Spina F, Patriarca F, Narni F, Benedetti F, Olivieri A, Corradini P. *Haematologica*. 2009;94:654-62.
- 10) Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Dodero A, **Carniti C**, Raganato A, Vendramin A, Farina L, Spina F, Carlo-Stella C, Di Terlizzi S, Milanesi M, Longoni P, Gandola L, Lombardo C, Corradini P. *Blood*. 2009;113:4771-9.
- 11) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, **Carniti C**, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo. *Leukemia*. 2007;21:2316-23.
- 12) NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Galiotta A, Gunby RH, Redaelli S, Stano P, **Carniti C**, Bachi A, Tucker PW, Tartari CJ,

- Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, Donella-Deana A, Marin O, Perrotti D, Gambacorti-Passerini C. *Blood*. 2007;110:2600-9.
- 13) RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cranston AN, **Carniti C**, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S, Mondellini P, Leyland J, Pierotti MA, Whittaker J, Taylor SS, Bongarzone I, Ponder BA. *Cancer Res*. 2006;66:10179-87.
  - 14) The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease. **Carniti C**, Belluco S, Riccardi E, Cranston AN, Mondellini P, Ponder BA, Scanziani E, Pierotti MA, Bongarzone I. *Am J Pathol*. 2006 Apr;168(4):1262-75.
  - 15) A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Cranston A, **Carniti C**, Martin S, Mondellini P, Hooks Y, Leyland J, Hodgson S, Clarke S, Pierotti M, Ponder BA, Bongarzone I. *Mol Endocrinol*. 2006:1633-43.
  - 16) RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor. Bongarzone I, **Carniti C**, Perego C, Mondellini P, Pierotti MA. *Tumori*. 2003 Sep-Oct;89(5):550-2. Review.
  - 17) Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Arighi E, Popsueva A, Degl'Innocenti D, Borrello MG, **Carniti C**, Perälä NM, Pierotti MA, Sariola H. *Mol Endocrinol*. 2004;18:1004-17.
  - 18) PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. **Carniti C**, Perego C, Mondellini P, Pierotti MA, Bongarzone I. *Cancer Res*. 2003 May 1;63(9):2234-43.
  - 19) RET and NTRK1 proto-oncogenes in human diseases. Alberti L, **Carniti C**, Miranda C, Roccato E, Pierotti MA. *J Cell Physiol*. 2003 May;195(2):168-86.
  - 20) Basic fibroblast growth factor messenger ribonucleic acid levels in human placentas from normal and pathological pregnancies. Di Blasio AM, **Carniti C**, Vigano P, Florio P, Petraglia F, Vignali M. *Mol Hum Reprod*. 1997 Dec;3(12):1119-23.
  - 21) Basic fibroblast growth factor messenger ribonucleic acid levels in eutopic and ectopic human endometrial stromal cells as assessed by competitive polymerase chain reaction amplification. Di Blasio AM, Centinaio G, **Carniti C**, Somigliana E, Viganò P, Vignali M. *Mol Cell Endocrinol*. 1995 Dec 29;115(2):169-75.
  - 22) Basic fibroblast growth factor and ovarian cancer. Di Blasio AM, **Carniti C**, Viganò P, Vignali M. *J Steroid Biochem Mol Biol*. 1995
  - 23) Separation and quantitation of reverse transcriptase polymerase chain reaction fragments of basic fibroblast growth factor by capillary electrophoresis in polymer networks. Gelfi C, Leoncini F, Righetti PG, Cremonesi L, di Blasio AM, **Carniti C**, Vignali M. *Electrophoresis*. 1995 May;16(5):780-3.
  - 24) Expression of the genes encoding basic fibroblast growth factor and its receptor in human granulosa cells. Di Blasio AM, Vigano P, Cremonesi L, **Carniti C**, Ferrari M, Ferrari A. *Mol Cell Endocrinol*. 1993 Oct;96(1-2):R7-11.